Research programme: anticancer radioimmunotherapeutics - Nordic Nanovector

Drug Profile

Research programme: anticancer radioimmunotherapeutics - Nordic Nanovector

Alternative Names: 177Lu-conjugated chimeric antibody (anti-CD37 ARC); chHH1 - Nordic Nanovector; Lu-177 chimeric anti-CD37 antibody radionuclide conjugate - Nordic Nanovector; Lu-177-conjugated anti-CD37 chimeric HH1antibody - Nordic Nanovector

Latest Information Update: 16 Dec 2016

Price : $50

At a glance

  • Originator Nordic Nanovector
  • Developer Nordic Nanovector; Norwegian Radium Hospital
  • Class Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical B cell lymphoma
  • No development reported Cancer

Most Recent Events

  • 06 Dec 2016 Nordic Nanovector plans a phase I trial for an undisclosed indication presumably in Norway
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Norway (Parenteral)
  • 27 Oct 2015 Preclinical trials in B-cell lymphoma in Norway (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top